Biomarin Pharmaceutical Inc (BMRN)
Return on equity (ROE)
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Net income | US$ in thousands | 426,859 | 167,645 | 141,561 | -64,080 | 854,029 |
| Total stockholders’ equity | US$ in thousands | 5,657,990 | 4,951,550 | 4,603,160 | 4,265,670 | 4,100,930 |
| ROE | 7.54% | 3.39% | 3.08% | -1.50% | 20.83% |
December 31, 2024 calculation
ROE = Net income ÷ Total stockholders’ equity
= $426,859K ÷ $5,657,990K
= 7.54%
Biomarin Pharmaceutical Inc's return on equity (ROE) has exhibited notable fluctuations over the years.
At year-end December 31, 2020, the ROE stood at a commendable 20.83%, reflecting strong profitability in relation to shareholders' equity. However, there was a significant decline by year-end December 31, 2021, with ROE dropping to -1.50%, indicating a negative return which may raise concerns regarding the company's ability to generate profits from shareholders' investments.
In subsequent years, Biomarin Pharmaceutical Inc's ROE showed a gradual recovery. By the end of December 31, 2022, the ROE had improved to 3.08%, suggesting a return to positive territory but still relatively low. The trend continued with a slight increase to 3.39% by December 31, 2023, indicating ongoing efforts to enhance profitability.
By the end of December 31, 2024, Biomarin Pharmaceutical Inc managed to achieve a more robust ROE of 7.54%, demonstrating a significant improvement compared to the previous years and suggesting enhanced efficiency in leveraging equity to generate returns for shareholders.
Overall, the fluctuating trend in Biomarin Pharmaceutical Inc's ROE highlights the company's evolving profitability performance and its utilization of shareholders' equity to generate returns, with recent years showing a positive momentum towards improved profitability.
Peer comparison
Dec 31, 2024